22nd July 2021
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here: https://nuformix.com/document-center/ Download News